Ambiguity a fact of life at the FDA, so is agency deference July 5, 2019 By Mari Serebrov No Comments With regulatory science always lagging innovation, ambiguity has long been a certainty at the FDA and is likely to become even more so as the pace of new technologies quickens.Read More